A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

• Status: Completed
• Trial end date: 2019-07-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effect of multiple dose administrations of Omeprazole on the pharmacokinetics of BMS-986205.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Linrodostat; Omeprazole

Criteria

Inclusion Criteria:

• Health male and female participants (not of childbearing potential) as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

• normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) greater than or equal to (>=) 80 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2)

• Body mass index (BMI) of 18.0 kilogram per meter square (kg/m^2) to 32.0 kg/m^2

• Women participants must have documented proof that they are not of childbearing potential

Exclusion Criteria:

• Women who are of childbearing potential or breastfeeding

• Active tuberculosis (TB) requiring treatment or documented latent TB within the previous 3 years

• Concomitant use of strong inhibitors or strong inducers of CYP3A4

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population